152 related articles for article (PubMed ID: 34854114)
1. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
2. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
3. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
4. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
[TBL] [Abstract][Full Text] [Related]
5. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides: successful re-treatment with brentuximab vedotin.
James M; Nakamura M; Whittaker S; Morris S
Br J Dermatol; 2024 May; 190(6):929-930. PubMed ID: 38470968
[No Abstract] [Full Text] [Related]
7. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
10. An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.
Pallazola VA; Deib G; Abha S; Geha RM; Kobayashi K
J Gen Intern Med; 2019 Nov; 34(11):2669-2674. PubMed ID: 31388911
[TBL] [Abstract][Full Text] [Related]
11. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
12. Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association.
Roccuzzo G; Cavallo F; Avallone G; Fava P; Conti L; Ribero S; Fierro MT; Quaglino P
Dermatol Ther; 2022 Apr; 35(4):e15309. PubMed ID: 35000253
[No Abstract] [Full Text] [Related]
13. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
14. Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.
Zhang C; Chairatchaneeboon M; Haun P; Landsburg D; Kim EJ
JAMA Dermatol; 2018 Jan; 154(1):109-110. PubMed ID: 29167875
[No Abstract] [Full Text] [Related]
15. Brentuximab vedotin: unexpectedly good response in CD30
Sun J; Wang Y
Br J Dermatol; 2019 Jun; 180(6):1300-1301. PubMed ID: 31157447
[No Abstract] [Full Text] [Related]
16. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides.
Torre-Castro J; Recio-Monescillo M; Castillo Bazan E; Díaz de la Pinta J; Rodríguez Pinilla M; Requena L; Córdoba R
Int J Dermatol; 2024 Jun; 63(6):828-830. PubMed ID: 38419393
[No Abstract] [Full Text] [Related]
17. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
[TBL] [Abstract][Full Text] [Related]
18. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
Maitrepierre F; Schissler C; Cribier B; Lipsker D
Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
[TBL] [Abstract][Full Text] [Related]
19. The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma.
Gao C; McCormack CJ; van der Weyden C; Twigger R; Buelens O; Lade S; Khoo C; Campbell BA; Goh M; McKelvie P; Prince HM
J Am Acad Dermatol; 2021 Jan; 84(1):185-187. PubMed ID: 32334059
[No Abstract] [Full Text] [Related]
20. Alitretinoin treatment in mycosis fungoides with CD30-positive large cell transformation.
Park J; Kwon O; Park K; Chung H
Clin Exp Dermatol; 2017 Apr; 42(3):341-342. PubMed ID: 28211143
[No Abstract] [Full Text] [Related]
[Next] [New Search]